Pharmacokinetics, pharmacodynamics, and tolerability of PSI 7851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2013
At a glance
- Drugs PSI 7851 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- 22 Mar 2013 Status changed from recruiting to completed.
- 31 Jul 2009 Positive preliminary results announced in a Pharmasset media release.
- 15 Jun 2009 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History